Streetwise Reports' Article Archives — Current Month (1)
Co. Reports Positive Results in Phase 2b/3 Alzheimer's Trial (12/05/2022)
Shares of Anavex Life Sciences Corp. traded 36% higher Friday after the company reported that during a Phase 2b/3 clinical trial of patients diagnosed with early Alzheimer's disease, its ANAVEX®2-73 (blarcamesine) met both key primary and secondary endpoints and demonstrated significant reductions in clinical decline.
More Archives
2022Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
